Marinomed Biotech Valuation
Is 93Z undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 93Z when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 93Z (€9) is trading below our estimate of fair value (€239.72)
Significantly Below Fair Value: 93Z is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 93Z?
Key metric: As 93Z is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 93Z's PS Ratio? | |
|---|---|
| PS Ratio | 2.3x |
| Sales | €6.60m |
| Market Cap | €15.25m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.3x |
| Enterprise Value/EBITDA | -5.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 93Z's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.6x | ||
B8FK Biofrontera | 0.8x | n/a | €17.0m |
SBX SynBiotic | 7.8x | 39.7% | €29.9m |
HIGH Cantourage Group | 28.6x | 38.6% | €56.1m |
0RX Redx Pharma | 13.3x | -37.6% | €65.0m |
93Z Marinomed Biotech | 2.3x | n/a | €15.3m |
Price-To-Sales vs Peers: 93Z is good value based on its Price-To-Sales Ratio (2.3x) compared to the peer average (12.6x).
Price to Sales Ratio vs Industry
How does 93Z's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 23 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 23 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 93Z is good value based on its Price-To-Sales Ratio (2.3x) compared to the European Pharmaceuticals industry average (3.1x).
Price to Sales Ratio vs Fair Ratio
What is 93Z's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.3x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 93Z's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.60
7D
-2.6%
1Y
86.3%
Perrigo
US$3.7b
Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.
PIG
US$25.29
7D
3.1%
1Y
-7.7%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.35
7D
-4.5%
1Y
-2.3%